MedPath

A study to evaluate Enhanced Visual Assessment System in detecting cervical cancer

Recruiting
Conditions
Cervical Cancer screening
Registration Number
CTRI/2017/03/008128
Lead Sponsor
Mobile ODT Mobile Optical Detection Technologies
Brief Summary

This study is a non randomized, observational screening study to detect cervical cancer using the low cost and effective Enhanced Visual Assesment System (EVA System) developed by Mobile ODT.

- This system is a low cost system comprised of 3 elements –

- **The scope** which is Mobile, lightweight, and durable medical device for magnified inspection that includes an ultra-bright light source with glare-reducing cross-polarization technology, a lens enabling up to 17 times magnification for superior imaging, and a rechargeable battery for up to 10 hours of continuous examinations.

- **The app-** Mobile phone based application allowing confidential data capture and review, remote expert decision support  and patient engagement through image review.

- **The Portal:** An online quality control, measurement and evaluation system facilitating screening, consultation, and program level analytic review from anywhere in the world.

The system is attempting to better the gold standard of PAP smear by introducing digital cervicography an advanced cervical cancer screening method, into primary screening, thus exploring the technology’s ability to reduce loss to follow up and provide easy care diagnosis.

A sample size of 1500-2000 patients will be taken during this study. During the study, using the EVA system, the patients detected with cervical cancer / precancerous conditions will be measured as will the patients detected with cervical cancer / precancerous conditions having negative initial screening results (PAP smear / HPV are –ve) will be measured.

The provider and patient satisfaction will also be measured.

There are numerous studies attempting to better the cervical cancer screening with regards to better sensitivity and specificity. If found to be successful, this study will help us significantly raise the standards of cervical screening

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Female
Target Recruitment
2000
Inclusion Criteria

Able to understand and consent to participating in the study.

Exclusion Criteria

Women previously detected with cervical cancer.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patients detected with cervical cancer / precancerous reasons6 months
Secondary Outcome Measures
NameTimeMethod
Provider and patient satisfaction with EVA System, consistent with utilization of the device6 months

Trial Locations

Locations (1)

Dr L H Hiranandani Hospital

🇮🇳

(Suburban), MAHARASHTRA, India

Dr L H Hiranandani Hospital
🇮🇳(Suburban), MAHARASHTRA, India
Dr Rakhee Sahu
Principal investigator
9820194413
rakhee.sahu@hiranandanihospital.org
Dr Renuka Matti
Principal investigator
9867056359
drrenumatti61@hotmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.